TARRYTOWN, N.Y., Aug. 22 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS) today announced that Paul Lubetkin has
been appointed to the position of Vice President and General Counsel,
effective September 4, 2007. Mr. Lubetkin will be responsible for the
overall planning, management and execution of the legal function, including
global intellectual property, transactional legal advice, securities and
funding, and commercial transactions. Mr. Lubetkin will report directly to
Michael V. Novinski, President and Chief Executive Officer. Emisphere
Technologies, Inc. is a biopharmaceutical company that focuses on a unique
and improved delivery of therapeutic molecules and pharmaceutical compounds
using its eligen(R) technology.

"Paul Lubetkin's understanding of business and legal issues, coupled
with his deep knowledge of pharmaceutical law, make him an ideal fit for
Emisphere," said Michael V. Novinski, President and Chief Executive Officer
of Emisphere Technologies, Inc. "Mr. Lubetkin also brings a real expertise
in Regulatory, SEC and Corporate Governance aligned with strong management
capabilities. We are very excited to have him bring this wealth of
experience to Emisphere."

Mr. Lubetkin is the previous Vice President and General Counsel of
Aptuit, Inc., a private global contract research organization providing
services to the pharmaceutical and biotechnology industries. He was
previously Senior Vice President, General Counsel and Secretary of Odyssey
Pharmaceuticals, Inc., a specialty pharmaceuticals company, where he
managed litigation, negotiated and supervised material transactions, and
provided a wide range of corporate and compliance advice. He is the former
Senior Vice President and General Counsel of CollaGenex Pharmaceuticals,
Inc., a publicly traded specialty pharmaceuticals company focused on the
dermatology market, and Senior Vice President, General Counsel, and
Secretary of PersonalPath Systems, Inc., a private care management and
internet health business that was purchased in 2003.

His prior experience also includes a decade as Vice President, General
Counsel, and Secretary of Regeneron Pharmaceuticals, Inc., a publicly
traded biotechnology company and a decade of working as a trial lawyer in
private practice and in the Division of Enforcement of the U.S. Securities
and Exchange Commission (SEC). During Mr. Lubetkin's in-house career in the
healthcare industry, he has provided counsel about corporate, corporate
governance, compliance, intellectual property, litigation, transactions,
and many other areas.

"This is a very exciting time to join the Emisphere team. There is a
robust pipeline and the Company stands poised to improve the lives of
countless patients," said Mr. Lubetkin. "I am eager to start building the
foundation of their legal function and help move the company forward."

Mr. Lubetkin received his J.D. (with distinction) at the University of
Iowa College of Law, Iowa City, Iowa, and his B.S. from Northwestern
University, Evanston, Illinois. He is a member of the American Bar
Association, the Association of Corporate Counsel, and various state bar
associations. He is also a trustee of the Gateway School of New York, an
accredited independent school for learning disabled children between the
ages of six and 12.

Emisphere's broad-based drug delivery technology platform, known as the
eligen(R) technology, is based on the use of proprietary, synthetic
chemical compounds, known as Emisphere(R) delivery agents, or "carriers."
Emisphere's eligen(R) technology makes it possible to deliver a therapeutic
molecule without altering its chemical form or biological integrity.

About Emisphere Technologies, Inc.

Emisphere Technologies, Inc. is a biopharmaceutical company that
focuses on a unique and improved delivery of therapeutic molecules and
pharmaceutical compounds using its eligen(R) technology. These molecules
and compounds could be currently available or are in pre-clinical or
clinical development. Such molecules or compounds usually cannot be
delivered by the oral route of administration or the benefits of these
compounds are limited due to poor bioavailability, slow on-set of action or
variable absorption. The eligen(R) technology can be applied to the oral
route of administration as well other delivery pathways, such as buccal,
per rectum, pulmonary, intra-vaginal or transdermal. The Web site is:
http://www.emisphere.com.

Safe Harbor Statement Regarding Forward-Looking Statements

The statements in this release and oral statements made by
representatives of Emisphere relating to matters that are not historical
facts (including without limitation those regarding future performance or
financial results, the timing or potential outcomes of research
collaborations or clinical trials, any market that might develop for any of
Emisphere's product candidates and the sufficiency of Emisphere's cash and
other capital resources) are forward-looking statements that involve risks
and uncertainties, including, but not limited to, the likelihood that
actual performance or results could materially differ, that future research
will prove successful, the likelihood that any product in the research
pipeline will receive regulatory approval in the United States or abroad,
the ability of Emisphere and/or its partners to develop, manufacture and
commercialize products using Emisphere's drug delivery technology, or
Emisphere's ability to fund such efforts with or without partners.
Emisphere undertakes no obligation to update any of these statements.
Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as to the date hereof. Accordingly any
forward-looking statements should be read in conjunction with the
additional risks and uncertainties detailed in Emisphere's filings with the
Securities and Exchange Commission, including those factors discussed under
the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file
no. 000-17758) filed on March 6, 2007, and our Quarterly Report on Form
10-Q for the quarter ended March 31, 2007, filed on May 7, 2007 (file no.
000-17758).

(Date:12/8/2016)... , Dec. 8, 2016 Biotheranostics today announced ... role of the Breast Cancer Index (BCI) in ... cancer are most at-risk for disease recurrence and ... results from three studies advancing the understanding of ... to tumor biology and inform decisions related to ...

(Date:12/8/2016)... 8, 2016 Eurofins announces the appointment of Sean ... Eurofins Scientific Inc. (ESI). Mr. Murray will bring ... and entrepreneurial experience in leading international business teams. As the National ... market to uphold Eurofins, status as the global leader in bio-analytical ... , , ...

(Date:12/8/2016)... ... December 08, 2016 , ... Opal Kelly, a leading producer ... using USB or PCI Express, announced the FOMD-ACV-A4, the company's first FPGA-on-Module for ... thin, SODIMM-style module that fits a standard 204-pin SODIMM socket for low-cost integrations ...

(Date:12/6/2016)... , Dec. 6, 2016 Valencell , the ... it has seen a third consecutive year of triple ... technology in 2016 with a 360 percent increase in ... This increase was driven by sales of its wrist ... interest in its technology for hearables for fitness and ...